Log in
Enquire now
Oncolys BioPharma

Oncolys BioPharma

Oncolys BioPharma is a Tokyo-based molecular diagnostics company developing therapy and diagnostics for cancer treatment and founded in 2004.

OverviewStructured DataIssuesContributors

Contents

oncolys.com/en
oncolys.com
Is a
Venture capital firm
Venture capital firm
Investor
Investor
Company
Company
Organization
Organization

Company attributes

Industry
Pharmaceutical industry
Pharmaceutical industry
Engineering
Engineering
Molecular diagnostics
Molecular diagnostics
Biopharmaceutical
Biopharmaceutical
Oncology
Oncology
Healthcare
Healthcare
Diagnosis
Diagnosis
...
Location
Japan
Japan
Tokyo
Tokyo
B2X
B2B
B2B
CEO
‌
Yasou Urata
Pitchbook URL
pitchbook.com/profiles...124260-40
Legal Name
Oncolys BioPharma Inc.
Number of Employees (Ranges)
11 – 50
Number of Employees
32
Founded Date
2004
Stock Symbol
4588
Exchange
Tokyo Stock Exchange
Tokyo Stock Exchange
Patents Assigned (Count)
4
Country
Japan
Japan

Venture Capital Firm attributes

Invested in
Precision Virologics
Precision Virologics

Other attributes

Company Operating Status
Active
Wikidata ID
Q30260641
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Associated Investment Funds

Accelerator Batches

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Oncolys BioPharma

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.